Coronavirus Disease 2019 Virus Research Articles

Development of highly adaptable RT-PCR methods for identifying Delta and BA.1 variants in inactivated COVID-19 vaccines.

Background The emergence and rapid spread of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), poses a significant threat to human health and public safety. While next-generation sequencing (NGS) is capable of detecting and tracking new COVID-19 variants for disease diagnosis and prevention, its high cost and time-consuming nature limit its widespread use. In this study, our aim was to develop a highly adaptable and accurate RT-PCR method for identifying the Delta or BA.1 variants in inactivated COVID-19 vaccine. We devised three two-plex RT-PCR methods targeting specific mutation sites: S: Δ156-157, S: N211-, L212I, and S: Δ142-144, Y145D. The RT-PCR method targeting the S: Δ156-157 mutation site was able to distinguish the Delta variant from other COVID-19 virus strains, while the RT-PCR methods targeting the S: N211-, L212I or S: Δ142-144, Y145D mutation sites were able to distinguish the BA.1 variant from other COVID-19 virus strains. We separately validated these three two-plex RT-PCR methods, and the results demonstrated good linearity, repeatability, reproducibility, and specificity for each method. Moreover, all three methods can be applied in the production of SARS-CoV-2 variant inactivated vaccines, enabling the identification of Delta or BA.1 variants in virus cultures as well as in inactivated vaccine stocks. This study presents a systematic approach to identify COVID-19 variants using multiple RT-PCR methods. We successfully developed three two-plex RT-PCR methods that can identify Delta and BA.1 variants based on specific mutation sites, and we completed the validation of these three methods.

Otitis media with effusion in patients with COVID-19: A single-center study in China

BackgroundThe swift global spread of coronavirus disease 2019 (COVID-19), a respiratory ailment primarily marked by pulmonary symptoms, has been linked to the involvement of various organs, including the intestines, kidneys, throat, and ears. Otitis media with effusion (OME), often succeeding an upper respiratory tract infection, mirrors its incidence. As a respiratory infectious disease, it prompts the query of whether the COVID-19 pandemic has spurred an uptick in OME and whether the COVID-19 virus persists in middle ear effusion (MEE) for an extended period. MethodsTo gauge the incidence of OME in the population during the COVID-19 pandemic, a tailored questionnaire was disseminated and subsequently analyzed. Assessing the rise in OME incidence during the pandemic, we compared the proportion of OME cases in the otology outpatient department between pandemic and non-pandemic periods. Statistical analysis involved a t-test. Simultaneously, MEE was collected from patients with COVID-19-associated OME during the pandemic to ascertain the presence of SARS-CoV-2 in MEE via polymerase chain reaction. ResultsBased on the questionnaire data, the estimated OME incidence in the population is approximately 31.4 %. In contrast to the non-pandemic period, the percentage variation in the OME outpatient proportion was 71.4 % (P < 0.05). Among the 61 MEE samples, 13 polymerase chain reaction results were positive, constituting 21.31 %. Nasopharyngeal swabs yielded negative results. Notably, only one patient experienced OME recurrence after 1 month of auripuncture. ConclusionsCOVID-19 can trigger an escalation in OME cases. Even when nasopharyngeal swabs show negative results, SARS-CoV-2 can endure in MEE for an extended duration, suggesting the potential for asymptomatic COVID-19 transmission and recurrence within the population.

COVID-19 virus mutation prediction with LSTM and attention mechanisms

Abstract Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2, is an emerging and rapidly spreading type of coronavirus. One of the most important reasons for the rapid spread of the COVID-19 virus are the frequent mutations of the COVID-19 virus. One of the most important methods to overcome mutations of the COVID-19 virus is to predict these mutations before they occur. In this study, we propose a robust HyperMixer and long short-term memory based model with attention mechanisms, HyperAttCov, for COVID-19 virus mutation prediction. The proposed HyperAttCov model outperforms several state-of-the-art methods. Experimental results have showed that the proposed HyperAttCov model reached accuracy 70.0%, precision 92.0%, MCC 46.5% on the COVID-19 testing dataset. Similarly, the proposed HyperAttCov model reached accuracy 70.2%, precision 90.4%, MCC 46.2% on the COVID-19 testing dataset with an average of 10 random trail. Besides, When the proposed HyperAttCov model with 10 random trail has been compared with compared to the study in the literature, the average of performance values has been increased by accuracy 7.18%, precision 37.39%, MCC 49.51% on the testing dataset. As a result, the proposed HyperAttCov can successfully predict mutations occurring on the COVID-19 dataset in the 2022 year.

The 100 most-cited articles in COVID-19: a bibliometric analysis.

Corona virus disease 2019 (COVID-19) pandemic, sparked by the emergence of a novel coronavirus in early 2020, has prompted a surge in published articles. This study aims to systematically analyse the characteristics and trends of impactful research in the field. The 100 most-cited publications associated with COVID-19 were identified by two independent reviewers using the 'Web of Science' database across all available journals up to the year 2023. Data collected include country, citation count, subject, level of evidence (using Oxford Centre for Evidence-Based Medicine System 2011), impact factor, funding, and study design. We identified 394 038 publications, and the 100 most-cited publications were ranked. These were cited by a total of 283 034 articles (median citation = 767), median impact factor of 66.9 and 72 articles with fundings. China (n = 44), USA (n = 19), and UK (n = 13) were the three highest contributors (n = 220 505). Most articles were level 5 evidence (n = 48), followed by level 3 (n = 28), 4 (n = 14), 2 (n = 7), and 1 (n = 3). The main subjects were mechanism of action and structures of SARS-CoV-2 virus (n = 18) and impact of COVID-19 on public health (n = 18). Publications in 2022 and 2023 predominantly focused on the impact of COVID-19. Majority of the highly cited studies were of low-to-moderate quality, with only 10 consisting of randomized controlled trials or systematic reviews with or without meta-analysis. These findings reflect a growing interest in understanding the impact of COVID-19 pandemic on public and mental health. This analysis found the potential for future double-blinded randomized controlled trials to validate existing findings.

Lab results of COVID-19 patients: Omicron vs delta variants

BACKGROUND The coronavirus disease 2019 (COVID-19) virus has been a world-known pandemic since February 2020. Multiple variances had been established; the most common variants in Israel were omicron and delta. AIM To analyze and compare laboratory values in the "omicron" and "delta" variants of the coronavirus by conducting follow-up examinations and laboratory audits on COVID-19 patients admitted to our institution. METHODS A retrospective study, two groups, 50 patients in each group. Patients examined positive for COVID-19 were divided into groups according to the common variant at the given time. We reviewed demographic data and laboratory results such as complete blood count and full chemistry, including electrolytes and coagulation parameters. RESULTS The mean age was 52%, 66.53 ± 21.7 were female. No significance was found comparing laboratory results in the following disciplines: Blood count, hemoglobin, and lymphocytes (P = 0.41, P = 0.87, P = 0.97). Omicron and delta variants have higher neutrophil counts, though they are not significantly different (P = 0.38). Coagulation tests: Activated paritial thromoplastin test and international normalized ratio (P = 0.72, P = 0.68). We found no significance of abnormality for all electrolytes. CONCLUSION The study compares laboratory results of blood tests between two variants of the COVID-19 virus – omicron and delta. We found no significance between the variants. Our results show the need for further research with larger data as well as the need to compare all COVID-19 variants.

TfrAdmCov: a robust transformer encoder based model with Adam optimizer algorithm for COVID-19 mutation prediction

ABSTRACT The development of vaccines and drugs is very important in combating the coronavirus disease 2019 (COVID-19) virus. The effectiveness of these developed vaccines and drugs has decreased as a result of the mutation of the COVID-19 virus. Therefore, it is very important to combat COVID-19 mutations. The majority of studies published in the literature are studies other than COVID-19 mutation prediction. We focused on this gap in this study. This study proposes a robust transformer encoder based model with Adam optimizer algorithm called TfrAdmCov for COVID-19 mutation prediction. Our main motivation is to predict the mutations occurring in the COVID-19 virus using the proposed TfrAdmCov model. The experimental results have shown that the proposed TfrAdmCov model outperforms both baseline models and several state-of-the-art models. The proposed TfrAdmCov model reached accuracy of 99.93%, precision of 100.00%, recall of 97.38%, f1-score of 98.67% and MCC of 98.65% on the COVID-19 testing dataset. Moreover, to evaluate the performance of the proposed TfrAdmCov model, we carried out mutation prediction on the influenza A/H3N2 HA dataset. The results obtained are promising for the development of vaccines and drugs.

Effects of Viral Infections Like COVID-19 on Head and Neck Cancers: The Role of Neutrophil-Lymphocyte Counts and Ratios.

Over the last three years, the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has had a global impact. COVID-19 has led to diagnostic and treatment delays in head and neck squamous cell cancers (HNSCCs). Both cancer and COVID-19 trigger systemic inflammatory responses that can result in cytokine storms, creating a favorable tumor microenvironment that supports tumor growth. Various studies have shown a positive association between increasing neutrophil-to-lymphocyte ratio (NLR) and disease severity in COVID-19. Studies have also shown that high NLR is associated with poor survival outcomes in cancer patients. Our aim is to investigate whether an increased NLRis linked to rapid tumor progression in patients with HNSCCwho have also been affected by infections like COVID-19 in the pre-operative period. This was a retrospective analysis of patients of HNSCC who were scheduled for surgery and had contracted COVID-19 in their pre-operative period between April 2021 and May 2021.The study analyzed pre- and post-COVID NLR in relation to disease progression in HNSCC.Statistical analysis was presented as an interquartile range and numbered with the percentage. StatisticalPackage for the Social Sciences (IBMSPSSStatisticsforWindows,IBMCorp., Version 26.0, Armonk,NY) was utilized for the analysis. We evaluated 200 operable cases of which 38/200 (20%) patients with HNSCC were COVID-19 positive. Out of those COVID-19-positive patients, 27/38 (71%) patients got operated. Around, 11/38 (28.9%) patients were inoperable. And, 14/27 (53.8%) operated patients also had a change in treatment plan. The mean duration from the joint clinic treatment plan to the date of surgery was 25.18 days.Patients who had contracted COVID-19 and had a change in their treatment plan due to disease progression exhibited mean NLR values of 3.84 (pre-COVID) and 11.11 (post-COVID), with respective medians of 3.04 and 10.50. These differences showed a statistically significant p-value of 0.000. In contrast, patients who had no change in treatment plan displayed mean NLR values of 4.51 (pre-COVID) and 9.70 (post-COVID), with respective medians of 3.47 and 3.42, resulting in with a non-significant p-value of 0.082. This is a one-of-its-kind study that has evaluated the role of elevated NLR in patients with a COVID-19 virus infection and its relationship with the clinical progression of the disease. The findings suggest that elevated NLR in patients with HNSCC, along with concurrent SARS-CoV2 infection, may contribute to accelerated disease progression with an increase in tumor burden and nodal metastasis.

Biomarkers can Predict COVID-19 Disease

Abstract:: Health professionals have been confronted with a series of challenges because of the ongoing pandemic of coronavirus disease 2019 (COVID-19). To save the greatest number of lives possible, it is essential to make a prompt diagnosis and admission to the hospital, as well as to stratify risks, make efficient use of intensive care services, choose appropriate treatments, monitor patients, and ensure a prompt discharge. Laboratory markers, also known as biomarkers, can provide additional information that is objective and has the potential to significantly influence various aspects of patient care. Clinical assessment is necessary, but laboratory markers can provide this information. The COVID-19 virus is not an infection that causes the respiratory system; rather, it is a multisystem disease that is caused by a diffuse system-wide process that involves a complex interplay of the immune, nervous, and endocrine systems in inflammatory and coagulative cascades. A wide variety of potential biomarkers have been uncovered because of a better understanding of the virus's effects on the body and how the body responds to them. Here, the pathophysiology and current data are examined in relation to various kinds of biomarkers, such as immunological and inflammation biomarkers, coagulation and hematological biomarkers, as well as cardiac, biochemical, and other biomarkers. This review provides a comprehensive analysis of the research on the association between biomarkers and clinical characteristics, viral load, treatment efficacy, and how this knowledge might most usefully contribute to patient care.

Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.

Available data regarding the safety and efficacy of sotrovimab in pregnant patients remain limited due to their exclusion from clinical trials. The COVID-19 International Drug Pregnancy Registry (COVID-PR) was established to gather comprehensive safety data from pregnant women who have received monoclonal antibody (mAb) or antiviral treatments for mild, moderate, or severe coronavirus disease 2019 (COVID-19) during pregnancy. Participants actively contributed self-reported data concerning their COVID-19 symptoms, in addition to sociodemographic and health-related characteristics. Obstetric, neonatal, and infant outcomes were also documented, with follow-up extending up to 12 months after childbirth. As of 30 November 2023, sotrovimab was administered to 39 participants enrolled in the COVID-PR. At the time of this report, 26 participants had given birth, with nine deliveries performed via cesarean section. The infants' birthweight ranged from 2381g to 4762g, with a mean of 3439.91g. Twenty-five infants were born at ≥37weeks. A total of 31 adverse events (AEs) were reported by 12 participants. The most frequently reported AE was gestational hypertension, observed in three participants. COVID-19 re-infection, fatigue, gestational diabetes, headache, and morning sickness were each reported by two participants. Of the reported AEs, eight (in five participants) were classified as serious, including four AEs (prolonged labor, pre-eclampsia, polyhydramnios, premature labor) that affected pregnancy. Seven of these eight serious AEs (SAEs) were found to be unrelated to sotrovimab, with one event (urinary retention) not assessable. A total of 44 AEs were reported in 19 delivered infants or in utero fetuses. The most common were COVID-19 (n=6 events), ear infection (n=5 events), neonatal dyspnea (n=3 events), and respiratory syncytial virus infection (n=3 events). Sixteen AEs (in 11 infants/fetuses) were classified as serious, including one report each of fetal cardiac disorder, congenital ankyloglossia, persistent right umbilical vein, and congenital hydronephrosis; the latter was considered a major congenital malformation. For all assessable SAEs, causality of sotrovimab treatment was ruled out based on lack of a temporal relationship alone or in combination with absence of a plausible mechanism. A sizable proportion of sotrovimab-treated participants in the COVID-PR had underlying medical conditions associated with an increased risk of severe COVID-19. None of the assessable SAEs were considered to be related to sotrovimab treatment.

Dynamics analysis and optimal control of delayed SEIR model in COVID-19 epidemic

The coronavirus disease 2019 (COVID-19) remains serious around the world and causes huge deaths and economic losses. Understanding the transmission dynamics of diseases and providing effective control strategies play important roles in the prevention of epidemic diseases. In this paper, to investigate the effect of delays on the transmission of COVID-19, we propose a delayed SEIR model to describe COVID-19 virus transmission, where two delays indicating the incubation and recovery periods are introduced. For this system, we prove its solutions are nonnegative and ultimately bounded with the nonnegative initial conditions. Furthermore, we calculate the disease-free and endemic equilibrium points and analyze the asymptotical stability and the existence of Hopf bifurcations at these equilibrium points. Then, by taking the weighted sum of the opposite number of recovered individuals at the terminal time, the number of exposed and infected individuals during the time horizon, and the system cost of control measures as the cost function, we present a delay optimal control problem, where two controls represent the social contact and the pharmaceutical intervention. Necessary optimality conditions of this optimal control problem are exploited to characterize the optimal control strategies. Finally, numerical simulations are performed to verify the theoretical analysis of the stability and Hopf bifurcations at the equilibrium points and to illustrate the effectiveness of the obtained optimal strategies in controlling the COVID-19 epidemic.

Targeting SIRT1 by Scopoletin to Inhibit XBB.1.5 COVID-19 Life Cycle.

Natural products have historically driven pharmaceutical discovery, but their reliance has diminished with synthetic drugs. Approximately 35% of medicines originate from natural products. Scopoletin, a natural coumarin compound found in herbs, exhibits antioxidant, hepatoprotective, antiviral, and antimicrobial properties through diverse intracellular signaling mechanisms. Furthermore, it also enhances the activity of antioxidants. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) causes viral pneumonia through cytokine storms and systemic inflammation. Cellular autophagy pathways play a role in coronavirus replication and inflammation. The Silent Information Regulator 1 (SIRT1) pathway, linked to autophagy, protects cells via FOXO3, inhibits apoptosis, and modulates SIRT1 in type-II epithelial cells. SIRT1 activation by adenosine monophosphate-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) enhances the autophagy cascade. This pathway holds therapeutic potential for alveolar and pulmonary diseases and is crucial in lung inflammation. Angiotensin-converting enzyme 2 (ACE-2) activation, inhibited by reduced expression, prevents COVID-19 virus entry into type-II epithelial cells. The coronavirus disease 2019 (COVID-19) virus binds ACE-2 to enter into the host cells, and XBB.1.5 COVID-19 displays high ACE-2-binding affinity. ACE-2 expression in pneumocytes is regulated by signal transducers and activators of transcription-3 (STAT3), which can increase COVID-19 virus replication. SIRT1 regulates STAT3, and the SIRT1/STAT3 pathway is involved in lung diseases. Therapeutic regulation of SIRT1 protects the lungs from inflammation caused by viral-mediated oxidative stress. Scopoletin, as a modulator of the SIRT1 cascade, can regulate autophagy and inhibit the entry and life cycle of XBB.1.5 COVID-19 in host cells.

Infection Control Practices in Dental Clinics and Dental Care Settings during COVID - 19's Spread: A Comprehensive Review

Coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, known as severe acute respiratory syndrome. Dental care units and settings face various problems relating to the transmission of disease during treatment and dental operations. The degree to which the healthcare system is ready affects how well coronavirus illness is managed. Blood, saliva, and mixed water droplets possessing the virus cause contamination of equipment used for dental treatment. Both patients and workers may become transmitters and infectors of COVID-19 through direct contact during dental operations. It is possible for dental professionals and patients to contract COVID-19 and spread it to others. The dental care routine is very effective as we discussed below the prevention steps are very effective. All healthcare workers at the dentistry clinics should collaborate to prevent the spread of the COVID-19 virus among patients. The primary aim is to make dental health care providers aware of the pathophysiology of COVID-19 and to increase their preparedness and understanding of this challenge, which will aid in controlling transmission. The information and data that collected will be useful for the dental community in providing effective patient management through evidence-based recommendations for infection control and disinfection protocols.

Differential Diagnosis in the Management of Acute Respiratory Infections through Point-of-Care Rapid Testing in a Post-Pandemic Scenario in Latin America: Special Focus on COVID-19, Influenza, and Respiratory Syncytial Virus

This review provides a comprehensive summary of evidence to explore the role and value of differential diagnosis in the management of Acute Respiratory Infections (ARIs) through point-of-care (POC) rapid testing in a post-pandemic scenario, paying particular attention to coronavirus disease 2019 (COVID-19), influenza, and respiratory syncytial virus (RSV). The document builds on a review of literature and policies and a process of validation and feedback by a group of seven experts from Latin America (LATAM). Evidence was collected to understand scientific and policy perspectives on the differential diagnosis of ARIs and POC rapid testing, with a focus on seven countries: Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru. The evidence indicates that POC rapid testing can serve to improve ARI case management, epidemiological surveillance, research and innovation, and evidence-based decision-making. With multiple types of rapid tests available for POC, decisions regarding which tests to use require the consideration of the testing purpose, available resources, and test characteristics regarding accuracy, accessibility, affordability, and results turnaround time. Based on the understanding of the current situation, this document provides a set of recommendations for the implementation of POC rapid testing in LATAM, supporting decision-making and guiding efforts by a broad range of stakeholders.

COVID-19 and CBRNE: Effects of the pandemic in the field of CBRNE.

The coronavirus disease 2019 (COVID-19) pandemic has affected our lives in all aspects, including key fields such as social interaction and economic supply chains. The field of chemical, biological, radiological, nuclear, and explosive substances (CBRNE) was already directly affected by the pandemic in that the COVID-19 virus is, in a sense, a biological agent. This paper elaborates on how the field of CBRNE has changed as a result of the COVID-19 pandemic. It does so by drawing on the results of an interview study with CBRNE practitioners (Fire Brigades, Law Enforcement Agencies, etc.) conducted as part of the European Union project PReparedness against CBRNE threats through cOmmon Approaches between security praCTItioners and the VulnerablE civil society, as well as findings from research literature on links between CBRNE and COVID-19. This paper highlights four areas where the influence of the pandemic on the CBRNE field has been evident. The four areas are as follows: preparedness for CBRNE incidents and likelihood of future CBRNE incidents (with a focus on terrorist attacks), CBRNE training and education, increased awareness of CBRNE-related behaviors and measures among the general public, and greater awareness of the needs of vulnerable groups (older people, etc.).

A comprehensive review of the interaction between COVID-19 spike proteins with mammalian small and major heat shock proteins.

Coronavirus disease 2019 (COVID-19) is a novel disease that had devastating effects on human lives and the country's economies worldwide. This disease shows similar parasitic traits, requiring the host's biomolecules for its survival and propagation. Spike glycoproteins severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 spike protein) located on the surface of the COVID-19 virus serve as a potential hotspot for antiviral drug development based on their structure. COVID-19 virus calls into action the chaperonin system that assists the attacker, hence favoring infection. To investigate the interaction that occurs between SARS-CoV-2 spike protein and human molecular chaperons (HSPA8 and sHSP27), a series of steps were carried out which included sequence attainment and analysis, followed by multiple sequence alignment, homology modeling, and protein-protein docking which we performed using Cluspro to predict the interactions between SARS-CoV-2 spike protein and human molecular chaperones of interest. Our findings depicted that SARS-CoV-2 spike protein consists of three distinct chains, chains A, B, and C, which interact forming hydrogen bonds, hydrophobic interactions, and electrostatic interactions with both human HSPA8 and HSP27 with -828.3 and -827.9 kcal/mol as binding energies for human HSPA8 and -1166.7 and -1165.9 kcal/mol for HSP27.

Retrospective Analysis of the Impact of SARS-CoV-2 (COVID-19) on Pregnancy and Neonatal Outcomes.

Background: The novel coronavirus disease 2019 (COVID-19) was more devastating in people with comorbidities such as advanced age and immunodeficiency. Another group affected by COVID-19 was pregnant women. Immunological changes during pregnancy and conditions such as gestational diabetes and pre-eclampsia that occur during pregnancy also have effects on the fetus. The aim of this study was to analyze the effects of PCR-proven COVID-19 infection during pregnancy on fetus and newborn. Methods: Between December 2019 and October 2021, data from pregnant women with COVID-19 symptoms or a history of contact with people with COVID-19, infected with PCR-proven COVID-19 virus, were analyzed retrospectively. Clinical and laboratory data of pregnant women were analyzed. Death data associated with COVID-19 were evaluated. Clinical and laboratory findings of newborns related to COVID-19 and mortality data related to COVID-19 were recorded. The study received approval from the Gazi Yasargil Training and Research Hospital ethics committee (09.07.2021/853). Results: We evaluated 327 pregnant women who were followed up in our hospital and whose deliveries ended in live birth, stillbirth, miscarriage, or curettage. One hundred eighty-five (56.6%) of the pregnant women had at least one COVID-19-related symptom. We evaluated the data of 306 live births, 21 intrauterine fetal deaths, and 13 postnatal deaths. Among the postnatal deaths, five infants succumbed directly due to COVID-19 infection. A total of 23 live-born babies (7.5%) were classified as small for gestational age (SGA), while 80 babies (26.1%) were born before 37 weeks of gestation, and 32 babies (10.4%) were born before 32 weeks. Cord blood gas analysis revealed that 19 infants (6.3%) had pH < 7 and base excess (BE) < -12. The rate of perinatal asphyxia was significantly higher in babies born to mothers who did not survive (p = 0.027). A considerable number of infants, 119 (40.3%), were admitted to the neonatal intensive care unit (NICU). Among the seven infants with positive PCR results admitted to the NICU, five (4.2%) did not survive. Conclusion: While COVID-19 infection in pregnancy seriously affects mortality and morbidity in pregnant women, it also causes mortality and morbidity on the fetus.

Occurrence of COVID-19 in cystic fibrosis patients: a review.

Cystic fibrosis (CF) is a genetic ailment caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. This autosomal recessive disorder is characterized by diverse pathobiological abnormalities, such as the disorder of CFTR channels in mucosal surfaces, caused by inadequate clearance of mucus and sputum, in addition to the malfunctioning of mucous organs. However, the primary motive of mortality in CF patients is pulmonary failure, which is attributed to the colonization of opportunistic microorganisms, formation of resistant biofilms, and a subsequent decline in lung characteristics. In December 2019, the World Health Organization (WHO) declared the outbreak of the radical coronavirus disease 2019 (COVID-19) as a worldwide public health crisis, which unexpectedly spread not only within China but also globally. Given that the respiration system is the primary target of the COVID-19 virus, it is crucial to investigate the impact of COVID-19 on the pathogenesis and mortality of CF patients, mainly in the context of acute respiratory distress syndrome (ARDS). Therefore, the goal of this review is to comprehensively review the present literature on the relationship between cystic fibrosis, COVID-19 contamination, and development of ARDS. Several investigations performed during the early stages of the virus outbreak have discovered unexpected findings regarding the occurrence and effectiveness of COVID-19 in individuals with CF. Contrary to initial expectancies, the rate of infection and the effectiveness of the virus in CF patients are lower than those in the overall population. This finding may be attributed to different factors, including the presence of thick mucus, social avoidance, using remedies that include azithromycin, the fairly younger age of CF patients, decreased presence of ACE-2 receptors, and the effect of CFTR channel disorder on the replication cycle and infectivity of the virus. However, it is important to notice that certain situations, which include undergoing a transplant, can also doubtlessly boost the susceptibility of CF patients to COVID-19. Furthermore, with an increase in age in CF patients, it is vital to take into account the prevalence of the SARS-CoV-2 virus in this population. Therefore, ordinary surveillance of CF patients is vital to evaluate and save the population from the capability of transmission of the virus given the various factors that contribute to the spread of the SARS-CoV-2 outbreak in this precise organization.

Comparison of Clinical, Laboratory Parameters, and Outcome of COVID-19-Positive and Negative Neonates Delivered from COVID-19-Positive Mothers

Abstract Objective Severe acute respiratory syndrome coronavirus 2 is a highly contagious respiratory viral infection that affects all individuals, although neonates are considered to be the most susceptible populations; therefore, this study was conducted to evaluate the clinical outcome and association between coronavirus disease 2019 (COVID-19)-positive mothers and newborns. Methods This cross-sectional study was conducted at a dedicated COVID-19 tertiary care hospital in India over a period of 1 year. The pregnant mothers infected with COVID-19 virus were enrolled with their newborn baby up to the age of 28 days. COVID-19 test was done by using a rapid antigen kit and further confirmed by reverse-transcription polymerase chain reaction. Results Prevalence of COVID-19-positive newborns born of COVID-19-positive mothers is reported at 8.4%. Female:male ratio was found to be 1:1.2. Raised D-dimer (88.9%) and C-reactive protein (88.9%) were the most common findings in COVID-19-positive newborns followed by leucopenia (33.3%). Among the COVID-19 newborns, Apgar score less than or equal to 7 and respiratory distress were found in 55.6 and 33.3%, respectively. Out of 9 COVID-19-positive newborns, two (22.2%) were expired, and out of 98 COVID-19-negative newborns, 4(4.1%) were expired. Conclusion This study revealed that severity of maternal symptoms is related to mortality of newborns. About 22.2% COVID-19-positive newborns expired, whereas 4.1% of COVID-19-negative newborns expired so risk of mortality increased among COVID-19-positive neonates as compared with negative ones. However, this study was conducted on a small sample size and further research with larger populations is needed to validate these findings.

COVID-19 infection segmentation using hybrid deep learning and image processing techniques

The coronavirus disease 2019 (COVID-19) epidemic has become a worldwide problem that continues to affect people’s lives daily, and the early diagnosis of COVID-19 has a critical importance on the treatment of infected patients for medical and healthcare organizations. To detect COVID-19 infections, medical imaging techniques, including computed tomography (CT) scan images and X-ray images, are considered some of the helpful medical tests that healthcare providers carry out. However, in addition to the difficulty of segmenting contaminated areas from CT scan images, these approaches also offer limited accuracy for identifying the virus. Accordingly, this paper addresses the effectiveness of using deep learning (DL) and image processing techniques, which serve to expand the dataset without the need for any augmentation strategies, and it also presents a novel approach for detecting COVID-19 virus infections in lung images, particularly the infection prediction issue. In our proposed method, to reveal the infection, the input images are first preprocessed using a threshold then resized to 128 × 128. After that, a density heat map tool is used for coloring the resized lung images. The three channels (red, green, and blue) are then separated from the colored image and are further preprocessed through image inverse and histogram equalization, and are subsequently fed, in independent directions, into three separate U-Nets with the same architecture for segmentation. Finally, the segmentation results are combined and run through a convolution layer one by one to get the detection. Several evaluation metrics using the CT scan dataset were used to measure the performance of the proposed approach in comparison with other state-of-the-art techniques in terms of accuracy, sensitivity, precision, and the dice coefficient. The experimental results of the proposed approach reached 99.71%, 0.83, 0.87, and 0.85, respectively. These results show that coloring the CT scan images dataset and then dividing each image into its RGB image channels can enhance the COVID-19 detection, and it also increases the U-Net power in the segmentation when merging the channel segmentation results. In comparison to other existing segmentation techniques employing bigger 512 × 512 images, this study is one of the few that can rapidly and correctly detect the COVID-19 virus with high accuracy on smaller 128 × 128 images using the metrics of accuracy, sensitivity, precision, and dice coefficient.

The causal association between COVID-19 and herpes simplex virus: a Mendelian randomization study.

The coronavirus disease 2019 (COVID-19) has emerged as a main global public health challenge. Additionally, herpes simplex virus type-1 (HSV-1) and type 2 (HSV-2) are widespread viruses that can cause orolabial herpes and genital herpes. Several clinical case reports have declared a possible association between the two, however, the causal relationship between them has not been clarified. This study utilized a Mendelian randomization (MR) approach for causality assessment between COVID-19 infection and HSV infection based on the latest public health data and Genome-Wide Association Study (GWAS) data. Multiple causal estimation methods, such as IVW, weighted median, simple mode, and weighted mode, were employed to validate the causal relation between COVID-19 infection and HSV infection, with COVID-19 infection, COVID-19 hospitalization, and severe COVID-19 as exposures, and HSV1/2 infection as the outcome. A reverse MR analysis was subsequently performed. MR analysis exhibited that COVID-19 infection was relevant to a reduced risk of HSV1 infection (p=7.603239e-152, OR=0.5690, 95%CI=0.5455-0.5935, IVW). Regarding the effect of COVID-19 infection on HSV2, MR analysis suggested that COVID-19 infection was correlated with an augmented risk of HSV2 infection (p=6.46735e-11, OR=1.1137, 95%CI=1.0782-1.1502, IVW). The reverse MR analysis did not demonstrate a reverse causal relationship between HSV and COVID-19. Altogether, COVID-19 infection might cause a decreased risk of HSV1 infection and an elevated risk of HSV2 infection.